English 
Español 
français 
العربية Search
Search
Introduction of Retatrutide is an investigational triple agonist drug targeting three receptors: GLP-1, GIP, and glucagon, developed for obesity and type 2 diabetes.
Mechanism: Mimics gut hormones to enhance insulin secretion, suppress appetite, and boost energy expenditure.
Efficacy: In Phase 2 trials, it demonstrated significant weight loss (up to ~24% of body weight at 48 weeks) and improved metabolic markers.
Development: Led by Eli Lilly, currently advancing to Phase 3 trials.
Potential: Aims to surpass existing GLP-1 drugs (e.g., semaglutide) by leveraging multi-receptor action for greater metabolic benefits.
Safety: Common side effects include gastrointestinal issues (nausea, diarrhea). Not yet FDA-approved; results remain under study.
Description of Retatrutide from Wuhan Fortuna Chemical Co.,Ltd
Basic Information of Retatrutide | |
Product Name | Retatrutide |
CAS NO. | |
Apperance | White to off white powder |
Assay | 99.8% |
Pacakge | 1kg/Foil Bag, 25kg/ Box/carton |
MOQ | 1kg |
Storage | |
Shelf Life | 2 Years |
Brand | Fortunachem |
Specifications(COA) of Retatrutide CAS 2381089-83-2
Items | Specifications | Results |
Appearance | Conforms | |
Solubility | Freely Soluble in water | Conforms |
Identifacation | The retention time of the main principal of the test Solution corresponds to that of the reference Solution，as obtained in the assay. | Conforms |
pH | 6.0 to 9.0 | 7.1 |
Clarity and color of the solution | The solution should be clear and colorless | Conforms |
Water content（K.F） | ≤8.0% | 1.8% |
Acetic acid | ≤0.5% | ND |
Trifiuoroacetic acid | ≤0.5% | ND |
Sodium ion | ≤5.0% | 1.8% |
Residual solvent | Methanol≤3000ppm | 10ppm |
Acetonitrile≤410ppm | 60ppm | |
Dichloromethane≤600ppm | ND | |
N,N-Dimethylformamide≤880pm | 40ppm | |
Related substances | Maximum single impurity≤0.5% | 0.32% |
Total impurities ≤2.0%. | 0.81% | |
Purity(HPLC) | ≥98.0% | 99.1% |
Bacterial Endotoxin test | ＜10EU/mg | Conforms |
Assay | 95.0%～105.0% | 99.8% |
Assay of Peptide | ≥85.0% | 95.5% |
Conclusion | The product comforms to In house standard | |
Introduction of Retatrutide is an investigational triple agonist drug targeting three receptors: GLP-1, GIP, and glucagon, developed for obesity and type 2 diabetes.
Mechanism: Mimics gut hormones to enhance insulin secretion, suppress appetite, and boost energy expenditure.
Efficacy: In Phase 2 trials, it demonstrated significant weight loss (up to ~24% of body weight at 48 weeks) and improved metabolic markers.
Development: Led by Eli Lilly, currently advancing to Phase 3 trials.
Potential: Aims to surpass existing GLP-1 drugs (e.g., semaglutide) by leveraging multi-receptor action for greater metabolic benefits.
Safety: Common side effects include gastrointestinal issues (nausea, diarrhea). Not yet FDA-approved; results remain under study.
Application of Retatrutide is an investigational peptide-based pharmaceutical drug developed by Eli Lilly and Company. It functions as a triple agonist, targeting three key receptors involved in metabolic regulation:
1. GLP-1 (glucagon-like peptide-1): Enhances insulin secretion, suppresses appetite, and slows gastric emptying.
2. GIP (glucose-dependent insulinotropic polypeptide): Modulates metabolism and fat storage.
3. Glucagon receptor: Increases energy expenditure and may improve lipid metabolism.
Indications: Primarily being studied for obesity and type 2 diabetes mellitus.
Clinical Trials: Demonstrated promising results in Phase 2 trials (as of 2023), with participants experiencing up to 24% mean weight loss over 48 weeks, surpassing efficacy of existing GLP-1/GIP agonists like tirzepatide (Mounjaro®) and semaglutide (Wegovy®).
Administration: Subcutaneous injection, likely once weekly.
Mechanism: The triple-action approach aims to synergistically improve glycemic control and promote weight loss while potentially mitigating side effects through balanced receptor activation.
Common side effects include gastrointestinal issues (nausea, diarrhea, vomiting), consistent with other GLP-1-based therapies.
Ongoing Phase 3 trials will further assess long-term safety and efficacy.
Expected to advance through Phase 3 trials, with potential FDA approval for obesity and diabetes in the coming years. If approved, it could become a leading option for patients requiring significant metabolic improvement.
Retatrutide represents a novel approach in metabolic therapeutics, highlighting the trend toward multi-targeted therapies for complex conditions like obesity and diabetes.
FAQ From Wuhan Fortuna Chemical Co.,Ltd | |
Q | Can I get a sample for free ? |
A | For small QTY and low value product, we can provide sample for free exclude shipping cost. For high value sample, we will charge the basic sample cost, but we can refund all the cost if customers place order after sample test. |
Q | How to confirm the product quality before placing orders ? |
A | Most of our products confirm to international standards like USP/EP/BP/JP/CP. We will provide COA/TDS/MSDS for customers to confirm the specification before placing order. |
Q | What is the payment you accept? |
A | For small and low value order, we accept CreditCard, MaterCard,VISA,Western Union and T/T.For large order, we can do T/T and L/C. Any pay on delivery or pay-after are not available for us. |
Q | What is your shipment way ? |
A | For less than 100kg gross weight order will ship with courier like FedEx or UPS, we support customers to place courier orders remotely by their account, we will package the goods well and wait for pick up.For more than 100kg goods, we will transport by Air or Sea according to customers' requirement. |
Q | How long is your after-sales service? |
A | We accept customer’s quality complaint in three month after customer received the goods. We provide tech.support for all-life if customer place order from our company. |
How do you treat quality complaint ? | |
A | We support customer to provide our products to any rightful third party testing organization to test our products according to the COA specification, if the test result is confirm with COA, we will take all the loss for customers. |
Wuhan Fortuna Chemical Co.,Ltd established in 2006, is a big integrative chemical enterprise being engaged in Pharmaceutical and Intermediates, Food and Feed additives, Fine chemicals,Biochemical and Reagent, which is the members of Hubei E-commerce Chamber.
Our company has professional persons who major in chemical R&D and sicentific management, supply fine chemical products with high quality and close service, also supply custom-tailored products according to our clients' requirement.
We have a positive and self-motivated management work team with a common philosophy, caring and commitment through teamwork, our team strive to achieve success in delighting our clients and ourselves.
Since Wuhan Fortuna Chemical Co., Ltd founded, we continuously innovate our products and improve our service, sales network. Hence, we initiate the first sale mode on net in China, which is the retail trade of small package bring along wholesale of diversified management modes. Our products are exported widely to South Korea, Vietnam, Australia, Europe and South America, highly recommended by our clients.We insist on the management creed “Market is our compass, Quality is our life, Credit is our soul”. Clients’ trust is our forward power, their satisfaction is our struggling goal.
Wuhan Fortuna Chemical Co.,Ltd is a professional manufacturer which provide Retatrutide with good quality and best price, welcome to contact us to get COA/TDS/MSDS of Retatrutide.
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!
Quick Links
Add:
E-mail:
